Iovance Biotherapeutics Stock Investor Sentiment
| IOVA Stock | USD 3.54 0.02 0.56% |
About 56% of Iovance Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iovance Biotherapeutics suggests that many traders are alarmed. The current market sentiment, together with Iovance Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Iovance Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 44
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Iovance Biotherapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Iovance Biotherapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Iovance Historical Sentiment
Although Iovance Biotherapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Iovance, such as negative comments on social media and news outlets, may cause fear in the market and push Iovance Biotherapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Iovance.
Iovance |
Iovance Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Iovance Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Iovance Biotherapeutics Historical Investor Sentiment
Investor biases related to Iovance Biotherapeutics' public news can be used to forecast risks associated with an investment in Iovance. The trend in average sentiment can be used to explain how an investor holding Iovance can time the market purely based on public headlines and social activities around Iovance Biotherapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Iovance Biotherapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Iovance Biotherapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Iovance Biotherapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Iovance Biotherapeutics.
Far too much social signal, news, headlines, and media speculation about Iovance Biotherapeutics that are available to investors today. That information is available publicly through Iovance media outlets and privately through word of mouth or via Iovance internal channels. However, regardless of the origin, that massive amount of Iovance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Iovance Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Iovance Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Iovance Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Iovance Biotherapeutics alpha.
Iovance Biotherapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Why Iovance Biotherapeutics Inc. Is Skyrocketing | 01/02/2025 |
2 | Peninsula biotech company sues insurance company to cover patients injuries in clinical trials | 01/24/2025 |
3 | Acquisition by Vogt Frederick G of 10417 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 01/27/2025 |
4 | Iovance Biotherapeutics Inc Q4 2024 Earnings EPS Loss of 0. ... | 02/27/2025 |
5 | Iovance Biotherapeutics, Inc. Q4 2024 Earnings Call Transcript | 02/28/2025 |
6 | Disposition of 07 shares by Graf Finckenstein Friedrich of Iovance Biotherapeutics subject to Rule 16b-3 | 03/03/2025 |
7 | Acquisition by Igor Bilinsky of 3516 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 03/04/2025 |
8 | Acquisition by Bellemin Jean-marc of 93750 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 03/05/2025 |
9 | Acquisition by Puri Raj K. of 117190 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 03/07/2025 |
10 | Down Nearly 80 percent From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up | 03/12/2025 |
11 | Disposition of 8334 shares by Puri Raj K. of Iovance Biotherapeutics subject to Rule 16b-3 | 03/14/2025 |
12 | Is Iovance Biotherapeutics, Inc. the Most Oversold Penny Stocks to Buy According to Analysts | 03/17/2025 |
13 | 11,400 Shares in Iovance Biotherapeutics, Inc. Purchased by Kazazian Asset Management LLC | 03/19/2025 |
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |